Vicept wraps $16M venture round

Malvern, PA-based Vicept Therapeutics has nailed down a $10 million investment, wrapping a $16 million Series A to back its development of a topical therapy for rosacea. The developer says that it now has enough money to push through Phase I and Phase II trials on V-101. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences. "We are focused on creating and developing novel products for use in the largest and fastest growing sectors of the dermatology market," said Neal Walker, president and chief executive officer of Vicept. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.